DE69934110T8 - Monomeres mp52/gdf-5 mit knochenmorphogener aktivität, und dieses enthaltende arzneimittel, zur vorbeugung und behandlung von knochen- und knorpelerkrankungen - Google Patents

Monomeres mp52/gdf-5 mit knochenmorphogener aktivität, und dieses enthaltende arzneimittel, zur vorbeugung und behandlung von knochen- und knorpelerkrankungen Download PDF

Info

Publication number
DE69934110T8
DE69934110T8 DE69934110T DE69934110T DE69934110T8 DE 69934110 T8 DE69934110 T8 DE 69934110T8 DE 69934110 T DE69934110 T DE 69934110T DE 69934110 T DE69934110 T DE 69934110T DE 69934110 T8 DE69934110 T8 DE 69934110T8
Authority
DE
Germany
Prior art keywords
bone
monomers
activity
morphoric
monomeres
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE69934110T
Other languages
English (en)
Other versions
DE69934110D1 (de
DE69934110T2 (de
Inventor
Shinji Kawai
Michio Chigasaki-shi KIMURA
Yoshifumi Minato-ku MURAKI
Mieko Higashimurayama-shi KATSUURA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbH
Original Assignee
Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbH filed Critical Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbH
Publication of DE69934110D1 publication Critical patent/DE69934110D1/de
Application granted granted Critical
Publication of DE69934110T2 publication Critical patent/DE69934110T2/de
Publication of DE69934110T8 publication Critical patent/DE69934110T8/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
DE69934110T 1998-05-22 1999-05-14 Monomeres mp52/gdf-5 mit knochenmorphogener aktivität, und dieses enthaltende arzneimittel, zur vorbeugung und behandlung von knochen- und knorpelerkrankungen Active DE69934110T8 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP10141379A JPH11335398A (ja) 1998-05-22 1998-05-22 新規な骨誘導活性を有する単量体蛋白質およびそれらからなる軟骨・骨疾患の予防および治療薬
JP14137998 1998-05-22
PCT/IB1999/000866 WO1999061611A1 (en) 1998-05-22 1999-05-14 Monomer protein with bone morphogenetic activity and medicinal agent containing the same for preventing and treating diseases of cartilage and bone

Publications (3)

Publication Number Publication Date
DE69934110D1 DE69934110D1 (de) 2007-01-04
DE69934110T2 DE69934110T2 (de) 2007-03-01
DE69934110T8 true DE69934110T8 (de) 2007-06-06

Family

ID=15290635

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69934110T Active DE69934110T8 (de) 1998-05-22 1999-05-14 Monomeres mp52/gdf-5 mit knochenmorphogener aktivität, und dieses enthaltende arzneimittel, zur vorbeugung und behandlung von knochen- und knorpelerkrankungen

Country Status (11)

Country Link
US (2) US7235241B2 (de)
EP (1) EP1078054B1 (de)
JP (2) JPH11335398A (de)
AT (1) ATE346151T1 (de)
AU (1) AU3530999A (de)
CY (1) CY1105933T1 (de)
DE (1) DE69934110T8 (de)
DK (1) DK1078054T3 (de)
ES (1) ES2272063T3 (de)
PT (1) PT1078054E (de)
WO (1) WO1999061611A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586388B2 (en) 1988-04-08 2003-07-01 Stryker Corporation Method of using recombinant osteogenic protein to repair bone or cartilage defects
EP1074620A1 (de) * 1999-08-06 2001-02-07 HyGene AG Monomer Protein der TGF-beta Familie
JPH11335398A (ja) * 1998-05-22 1999-12-07 Hoechst Marion Roussel Kk 新規な骨誘導活性を有する単量体蛋白質およびそれらからなる軟骨・骨疾患の予防および治療薬
JP2002306163A (ja) * 2001-04-11 2002-10-22 Chemo Sero Therapeut Res Inst 大腸菌を宿主とする遺伝子組換えヒトトロンビンの調製方法
FI116827B (fi) 2001-08-24 2006-03-15 Univ Zuerich Luun morfogeneettisen proteiinin deleetiomutantti, sitä sisältävä farmaseuttinen koostumus ja sen käyttö
ES2427177T3 (es) * 2004-04-27 2013-10-29 Galapagos N.V. Métodos, agentes y ensayos de detección de compuestos para inducir diferenciación de células de mamífero no diferenciadas para dar lugar a osteoblastos
US8188226B2 (en) 2005-11-18 2012-05-29 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh High activity growth factor mutants
PT1989546T (pt) * 2006-02-28 2016-12-05 Centre Nat De La Rech Scient (Cnrs) Rastreio de compostos anti-cancerígenos usando a actividade da netrina-1
GB0604966D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Medicaments and proteins
WO2008089987A1 (en) * 2007-01-25 2008-07-31 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Use of gdf-5 for the improvement or maintenance of dermal appearance
EP2019117A1 (de) * 2007-07-27 2009-01-28 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Optimiertes Reinigungsverfahren für rekombinantes Wachstumsfaktorprotein
JP5837930B2 (ja) 2010-07-30 2015-12-24 ビオファーム・ゲゼルシャフト・ツァ・ビオテヒノロジッシェン・エントヴィックルング・フォン・ファルマカ・エムベーハー 創傷の治癒を加速する医薬送達装置及び増殖因子製剤
CN102382187B (zh) * 2011-05-03 2013-05-22 中国人民解放军军事医学科学院放射与辐射医学研究所 Fbxl15蛋白片段及其编码基因和应用
EP2537538A1 (de) 2011-06-22 2012-12-26 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH Bioresorbierbarer Wundverband
EP2602264A1 (de) 2011-12-05 2013-06-12 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH GDF-5-Mutant zur Induzierung der Knorpelbildung
US11464888B2 (en) 2017-06-12 2022-10-11 Warsaw Orthopedic, Inc. Moldable formulations containing an oxysterol in an acellular tissue matrix
EP4076502A1 (de) 2019-12-18 2022-10-26 Merck Patent GmbH Verwendung der gdf-5-mutante zur behandlung von schmerzen und knorpelzerstörung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158934A (en) * 1989-09-01 1992-10-27 Genentech, Inc. Method of inducing bone growth using TGF-β
US5208219A (en) * 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
DE69434651T2 (de) * 1993-12-07 2007-03-08 Genetics Institute, Inc., Cambridge Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
JPH0931098A (ja) * 1995-07-24 1997-02-04 Hoechst Japan Ltd 新規なタンパク質ｈｍｗヒトｍｐ５２
JPH11335398A (ja) * 1998-05-22 1999-12-07 Hoechst Marion Roussel Kk 新規な骨誘導活性を有する単量体蛋白質およびそれらからなる軟骨・骨疾患の予防および治療薬

Also Published As

Publication number Publication date
ES2272063T3 (es) 2007-04-16
JPH11335398A (ja) 1999-12-07
US7638129B2 (en) 2009-12-29
AU3530999A (en) 1999-12-13
EP1078054B1 (de) 2006-11-22
DE69934110D1 (de) 2007-01-04
US7235241B2 (en) 2007-06-26
WO1999061611A1 (en) 1999-12-02
EP1078054A1 (de) 2001-02-28
ATE346151T1 (de) 2006-12-15
DK1078054T3 (da) 2007-03-12
US20060019886A1 (en) 2006-01-26
PT1078054E (pt) 2007-02-28
JP2002516098A (ja) 2002-06-04
US20080318856A1 (en) 2008-12-25
CY1105933T1 (el) 2011-04-06
DE69934110T2 (de) 2007-03-01
JP4272357B2 (ja) 2009-06-03

Similar Documents

Publication Publication Date Title
DE69934110T8 (de) Monomeres mp52/gdf-5 mit knochenmorphogener aktivität, und dieses enthaltende arzneimittel, zur vorbeugung und behandlung von knochen- und knorpelerkrankungen
Carreira et al. Bone morphogenetic proteins: promising molecules for bone healing, bioengineering, and regenerative medicine
JP3681069B2 (ja) Ｂｍｐ−１１組成物
Hannallah et al. Retroviral delivery of Noggin inhibits the formation of heterotopic ossification induced by BMP-4, demineralized bone matrix, and trauma in an animal model
BR0107613A (pt) Bloqueio do crescimento de axÈnios mediado por receptor nogo
AU2002305450A1 (en) Proteomimetic compounds and methods
KR19990014917A (ko) Bmp-15 조성물
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
DE60203692T2 (de) Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
ITPD920071A1 (it) Impiego di preparazioni di acido ialuronico per la formazione di tessuto osseo
US9200048B2 (en) High activity growth factor mutants
DE69729145D1 (de) Reagenz und Verfahren zur Inhibierung der N-RAS Expression
ATE264913T1 (de) Protease-resistente analoge des thrombomodulin
ATE255411T1 (de) Hyaluronsäurerezeptoren bindende stoffe und deren verwendung zur behandlung von tumoren und restenose
AU4312093A (en) Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections
ATE278014T1 (de) Target zur behandlung von atherosklerose, fettleibigkeit und diabetis typ ii
DE69630948T2 (de) Peptide und medikamente für knochenkrankheiten welche diese peptide als aktive bestandteile beinhalten
ATE245421T1 (de) Pharmazeutische zusammensetzung welche riluzol und gabapentin enthält zur behandung von motoneuronalen krankheiten
JP2011522565A (ja) 新規ｂｍｐ−１２関連タンパク質およびその製造方法
DE69928814D1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
RU95107870A (ru) Способ лечения послеоперационной цилиохориоидальной отслойки

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: KAWAI, SHINJI, F-75014 PARIS, FR

Inventor name: KIMURA, MICHIO, CHIGASAKI-SHI, KANAGAWA 253-00, JP

Inventor name: MURAKI, YOSHIFUMI, MINATO-KU, TOKYO 107-8465, JP

Inventor name: KATSUURA, MIEKO, HIGASHIMURAYAMA-SHI, TOKYO 18, JP

8364 No opposition during term of opposition